AU2011344652B2 - HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof - Google Patents

HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof Download PDF

Info

Publication number
AU2011344652B2
AU2011344652B2 AU2011344652A AU2011344652A AU2011344652B2 AU 2011344652 B2 AU2011344652 B2 AU 2011344652B2 AU 2011344652 A AU2011344652 A AU 2011344652A AU 2011344652 A AU2011344652 A AU 2011344652A AU 2011344652 B2 AU2011344652 B2 AU 2011344652B2
Authority
AU
Australia
Prior art keywords
seq
hla
peptides
peptide
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011344652A
Other languages
English (en)
Other versions
AU2011344652A1 (en
Inventor
Cecile Gouttefangeas
Peter Lewandrowski
Hans-Georg Rammensee
Stefan Stevanovic
Toni Weinschenk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immatics Biotechnologies GmbH
Original Assignee
Immatics Biotechnologies GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2010/069675 external-priority patent/WO2011073215A2/en
Application filed by Immatics Biotechnologies GmbH filed Critical Immatics Biotechnologies GmbH
Publication of AU2011344652A1 publication Critical patent/AU2011344652A1/en
Assigned to IMMATICS BIOTECHNOLOGIES GMBH reassignment IMMATICS BIOTECHNOLOGIES GMBH Amend patent request/document other than specification (104) Assignors: IMMATICS BIOTECHNOLOGIES GMBH
Application granted granted Critical
Publication of AU2011344652B2 publication Critical patent/AU2011344652B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K40/4276—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2011344652A 2010-12-14 2011-11-14 HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof Ceased AU2011344652B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPCT/EP2010/069675 2010-12-14
PCT/EP2010/069675 WO2011073215A2 (en) 2009-12-14 2010-12-14 Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
PCT/EP2011/070024 WO2012079878A2 (en) 2010-12-14 2011-11-14 Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2011344652A1 AU2011344652A1 (en) 2013-05-23
AU2011344652B2 true AU2011344652B2 (en) 2015-11-19

Family

ID=44983532

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011344652A Ceased AU2011344652B2 (en) 2010-12-14 2011-11-14 HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof

Country Status (9)

Country Link
JP (1) JP6032853B2 (enExample)
KR (1) KR20130126671A (enExample)
CN (1) CN103547283A (enExample)
AU (1) AU2011344652B2 (enExample)
CA (1) CA2821582A1 (enExample)
MX (1) MX2013006758A (enExample)
NZ (1) NZ609916A (enExample)
SG (1) SG191154A1 (enExample)
WO (1) WO2012079878A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102013012432A1 (de) * 2013-07-29 2015-01-29 Eberhard Karls Universität Tübingen Medizinische Fakultät Immuntherapie von Prostatakrebs
EP3131584B1 (en) * 2014-04-16 2022-01-12 Biocon Limited Stable protein formulations comprising a molar excess of sorbitol
JP7269733B2 (ja) * 2015-06-12 2023-05-09 レンティジェン・テクノロジー・インコーポレイテッド 操作されたｔ細胞を用いて癌を処置するための方法
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201521746D0 (en) * 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
GB201602918D0 (en) * 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
GB201603987D0 (en) * 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
EP4317432A3 (en) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH T cell receptors with improved pairing
CN116693695A (zh) * 2017-02-12 2023-09-05 百欧恩泰美国公司 基于hla的方法和组合物及其用途
KR102215578B1 (ko) * 2019-03-28 2021-02-15 한국과학기술연구원 인간 백혈구 항원에 특이적으로 결합하는 펩타이드 및 이의 용도

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA725596A (en) 1960-08-26 1966-01-11 J. Wretlind Arvid Method of preparing intravenously injectable fat emulsions free from side reactions or complications
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
CA2394741A1 (en) * 1999-12-21 2001-06-28 Epimmune Inc. Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US20020081680A1 (en) * 2000-04-17 2002-06-27 Jiangchun Xu Compositions and methods for the therapy and diagnosis of prostate cancer
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
US20030235533A1 (en) * 2002-02-19 2003-12-25 Idec Pharmaceuticals Corporation Prostate specific genes and the use thereof in design or therapeutics
EP2181595A1 (en) * 2002-08-16 2010-05-05 Yeda Research And Development Company Ltd. Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
WO2004053075A2 (en) * 2002-12-05 2004-06-24 Diadexus, Inc. Compositions, splice variants and methods relating to breast specific genes and proteins
WO2005033265A2 (en) * 2003-04-25 2005-04-14 Epimmune Inc. Optimized multi-epitope constructs and uses thereof
US8435507B2 (en) * 2004-08-19 2013-05-07 University Of Maryland Prostate-specific antigen-derived MHC class II restricted peptides and their use in vaccines to treat or prevent prostate cancer
PL1642905T3 (pl) 2004-10-02 2009-04-30 Immatics Biotechnologies Gmbh Epitopy immunogenicznych komórek pomocniczych T z antygenów guzów ludzkich oraz sposoby immunoterapeutyczne wykorzystujące te epitopy
EP1806358B1 (en) 2005-09-05 2010-03-17 Immatics Biotechnologies GmbH Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
DE602008000891D1 (de) * 2008-04-30 2010-05-12 Immatics Biotechnologies Gmbh Neuartige Formulierungen von Tumor-assoziierten Peptiden, welche an menschliche Leukozytenantigene der Klasse I oder II für Impfungen binden
RS53872B2 (sr) * 2008-05-14 2018-06-29 Immatics Biotechnologies Gmbh Novi i snažni mhc peptidi klase ii izvedeni iz survivina i neurokana
RS53782B1 (sr) * 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KIESSLING ET AL: "Advances in Specific Immunotherapy for Prostate Cancer" , EUROPEAN UROLOGY, ELSEVIER BV, NL, vol. 53, no. 4, 26 November 2007 (2007-11-26). pages 694-708, *

Also Published As

Publication number Publication date
WO2012079878A2 (en) 2012-06-21
JP2014502961A (ja) 2014-02-06
WO2012079878A3 (en) 2012-08-09
JP6032853B2 (ja) 2016-11-30
CN103547283A (zh) 2014-01-29
MX2013006758A (es) 2013-08-01
AU2011344652A1 (en) 2013-05-23
SG191154A1 (en) 2013-07-31
KR20130126671A (ko) 2013-11-20
NZ609916A (en) 2015-03-27
CA2821582A1 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
US9023802B2 (en) HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
US9023804B2 (en) HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
US9132177B2 (en) Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers
AU2008281013B2 (en) Composition of tumour-associated peptides and related anti-cancer vaccine
AU2011344652A1 (en) HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
US8653035B2 (en) Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
RS53872B1 (sr) Novi i snažni mhc peptidi klase ii izvedeni iz survivina i neurokana
EP2651434A2 (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
Class et al. Patent application title: COMPOSITION OF TUMOR-ASSOCIATED PEPTIDES AND RELATED ANTI-CANCER VACCINE FOR THE TREATMENT OF GASTRIC CANCER AND OTHER CANCERS Inventors: Jens Fritsche (Tuebingen, DE) Jens Fritsche (Tuebingen, DE) Toni Weinschenk (Aichwald, DE) Steffen Walter (Reutlingen, DE) Steffen Walter (Reutlingen, DE) Peter Lewandrowski (Tuebingen-Hirschau, DE) Peter Lewandrowski (Tuebingen-Hirschau, DE) Harpeet Singh (Tuebingen, DE) Assignees: IMMATICS BIOTECHNOLOGIES GMBH
Class et al. Patent application title: COMPOSITION OF TUMOR-ASSOCIATED PEPTIDES AND RELATED ANTI-CANCER VACCINE FOR THE TREATMENT OF GLIOBLASTOMA (GBM) AND OTHER CANCERS Inventors: Toni Weinschenk (Aichwald, DE) Oliver Schoor (Tubingen, DE) Oliver Schoor (Tubingen, DE) Claudia Trautwein (Wuelfrath, DE) Claudia Trautwein (Wuelfrath, DE) Norbert Hilf (Kirchentellinsfurt, DE) Norbert Hilf (Kirchentellinsfurt, DE) Steffan Walter (Reutlingen, DE) Harpreet Singh (Tuebingen, DE) Harpreet Singh (Tuebingen, DE) Assignees: IMMATICS BIOTECHNOLOGIES GMBH
HK1180701B (en) Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired